This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Alere Responds To Institutional Shareholder Services Recommendation

WALTHAM, Mass., July 26, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company" or "Alere"), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today issued the following statement in response to a report by Institutional Shareholder Services (ISS) regarding Alere's 2013 Annual Meeting of Stockholders, to be held on August 7, 2013:

ISS reached the wrong conclusion in failing to recommend that stockholders elect all of Alere's highly qualified director nominees.  ISS neglected to consider critical information, giving our stockholders an incomplete picture of the choices they face.

By its own admission, ISS's analysis does not include any evaluation of the dissident's proposed strategy for Alere.  In our view, a recommendation that does not even consider the merits of the dissident's strategy is woefully incomplete.  In a contested election, the business plans put forward by the Company and the dissident should be a critical consideration for stockholders.  ISS's methodology is to consider whether change is warranted, apparently without regard to what that change is.  Coppersmith has a pre-determined agenda focused on financial engineering that we believe will destroy long-term value.

ISS also fails to consider which director candidates are most likely to implement change that is actually beneficial.  ISS's analysis ignores the qualifications of the Company's Board nominees, whom we believe are vastly more qualified than the Coppersmith nominees.  Alere's Board nominated the former CEO of Stryker Corporation, and Coppersmith nominated his former CFO who, after a long career at Stryker and an eight-month term as interim CEO, was passed over by the Stryker Board for the full-time CEO position in favor of another internal candidate who had been at Stryker for 18 months.  Our stockholders should be very concerned that Coppersmith's other candidates have literally no operating experience in the highly regulated healthcare industry; in contrast, our Board nominated the former CEO of AstraZeneca and the former CEO of King Pharmaceuticals, both highly successful healthcare companies.  ISS does not explain why stockholders should vote for less qualified candidates who lack the industry experience to even know where to begin to formulate a strategy for a business as global and as complex as ours.  Two of Coppersmith's nominees have never served on the board of a public company, and we believe the Alere Board should not be their training ground.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs